Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for major depressive disorder, or MDD, later this year.
Source link
This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho
Date:
Share post:
